• Acculis (Denmead, UK) reported the extension of the worldwide launch of its Microwave Tissue Ablation (MTA) system for the coagulation of soft tissue in open surgery. The system is being used to treat liver cancers. The company said that MTA is the only FDA 510(k)-cleared, single-needle, high power 2.45GHz microwave system. It achieves 5 cm x 6.5 cm coagulations with single eight-minute applications and 4.3 cm x 6 cm diameter coagulations in only four minutes. The company said the system surpasses contemporary low-power 915MHz microwave systems which require complex multiple needle placements and longer times to achieve equivalent coagulations. Acculis said that the system was first distributed “to a cohort of the world’s leading cancer centers.” The roll-out is now being extended through the recruitment of distributors in several European countries, as well as in South America and Asia. “The MTA System has proven itself as an important additional tool for the liver surgeon,” said Acculis CEO Stuart McIntyre. Acculis is a device company developing microwave energy ablation systems for oncology applications. It is part of the Microsulis (Denmead) group of companies.